Home page Products and systems Key Applications Labware and Consumables Service and Support About Us Career Opportunities News and Events Contact Us
Current news
Conference Calendar
Webinars
 
 
 
View the latest news stories

<Back to current news

Press Release - for immediate release

20 April 2018

Sartorius Stedim Biotech Introduces Mini Microcarrier Bioreactor for Culturing Adherent Cells

• New vessel for ambr® 250 ht system will enable cost-effective, scalable process development of vaccines in cell culture

• Premieres at the BPI European Summit in Amsterdam

Goettingen, GER – 20 April 2018: Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry today announced the launch of a new mini bioreactor vessel for its ambr® 250 high throughput (ht) system. This new vessel, which is designed for optimal growth of adherent cells on microcarriers will enable rapid, scalable cell culture process development of vaccines. It will be shown at the BPI European Summit in Amsterdam, The Netherlands (April 23-25) (Booth 47).

The new single-use mini bioreactor for microcarrier culture is, has a working volume of 100-250 mL and features a single Elephant Ear impeller. This impeller type generates optimum mixing and suspension of microcarriers, allowing adherent cells to grow over the entire microcarrier surface. The new mini vessel is based on cell culture bioreactors in the ambr 250 ht system. Utilizing this bioreactor on the ambr 250 ht system will allow rapid scale-up of optimized adherent cell culture processes to SSB’s BIOSTAT® STR range of pilot and manufacturing scale stirred bioreactors. This results in shorter process development timelines than would be achieved by scientists using benchtop bioreactors and spinner flasks.

Simple to set up and use on the ambr 250 ht, this new single-use mini bioreactor minimizes set-up and turnaround time. With up to 24 bioreactors per ambr 250 ht system, the technology is ideal for Design of Experiments (DoE) studies to optimize process development for vaccine manufacturing using a Quality by Design (QbD) approach.

The new vessel has been tested in collaboration with bioprocess experts at Aston University and University College London as part of an Innovate UK funded project. During these studies, all the cell culture parameters were controlled by the ambr 250 ht automated workstation. The results showed that the new microcarrier vessel design enabled growth to confluence of Vero cells on Cytodex microcarriers’ surface.

“There has been increasing interest in using microcarriers for culturing adherent cell lines in single-use stirred bioreactors as they offer a cost-effective alternative to two-dimensional approaches for vaccine production using T-flasks and roller bottles,” stated Dr Barney Zoro, ambr Product Manager at Sartorius Stedim Biotech. “We are proud to be introducing our new ambr 250 mini bioreactor for culturing adherent cells at the BPI European Summit. Scientists visiting us on Booth 47 will find out how they can use our new mini bioreactor as a predictive model to help shorten their process development timelines and reduce their vaccine manufacturing costs.”

For further information, please contact:

Barney Zoro - ambr 250 Product Manager

York Way, Royston, Hertfordshire, SG8 5WY, UK
Tel: +44 1763 227200 Fax: +44 1763 227201





<Back to current news

 

 

 

Royston Office: Tel: +44 (0) 1763 227200 | European Service & Support: Tel: +44 (0) 1763 227333 | US Service & Support: Tel: +1 302 478 9060